Literature DB >> 24991829

Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.

Andrew Poklepovic1, David A Gewirtz2.   

Abstract

The premise of inhibiting autophagy to overcome resistance to chemotherapy has been investigated in 5 clinical phase I trials combining hydroxychloroquine with vorinostat, temsirolimus, temozolomide, or bortezomib. These studies have provided a number of insights relating to the tolerability of the combination treatments. In addition, these studies should provide guidance in the planning and design of future trials to directly determine whether the strategy of autophagy inhibition could prove useful in the treatment of various malignancies.

Entities:  

Keywords:  autophagy; bortezomib; hydroxychloroquine; temozolomide; temsirolimus; vorinostat

Mesh：

Substances：

Year:  2014        PMID： 24991829      PMCID： PMC4203528          DOI： 10.4161/auto.29428

Source DB:  PubMed          Journal:  Autophagy        ISSN： 1554-8627            Impact factor:   16.016


  8 in total

Review 1.  The four faces of autophagy: implications for cancer therapy.

Authors:  David A Gewirtz
Journal:  Cancer Res       Date:  2014-01-23       Impact factor: 12.701

2.  Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Authors:  Dan T Vogl; Edward A Stadtmauer; Kay-See Tan; Daniel F Heitjan; Lisa E Davis; Laura Pontiggia; Reshma Rangwala; Shengfu Piao; Yunyoung C Chang; Emma C Scott; Thomas M Paul; Charles W Nichols; David L Porter; Janeen Kaplan; Gayle Mallon; James E Bradner; Ravi K Amaravadi
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

3.  Hydroxychloroquine-induced myopathy.

Authors:  Jun-Beom Kwon; Anatole Kleiner; Koto Ishida; Justin Godown; Emma Ciafaloni; R John Looney
Journal:  J Clin Rheumatol       Date:  2010-01       Impact factor: 3.517

4.  Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Authors:  Devalingam Mahalingam; Monica Mita; John Sarantopoulos; Leslie Wood; Ravi K Amaravadi; Lisa E Davis; Alain C Mita; Tyler J Curiel; Claudia M Espitia; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

Review 5.  Hydrochloroquine retinopathy: characteristic presentation with review of screening.

Authors:  Christopher R Stelton; Daniel B Connors; Sandeep S Walia; Harpreet S Walia
Journal:  Clin Rheumatol       Date:  2013-03-21       Impact factor: 2.980

6.  Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.

Authors:  Reshma Rangwala; Robert Leone; Yunyoung C Chang; Leslie A Fecher; Lynn M Schuchter; Amy Kramer; Kay-See Tan; Daniel F Heitjan; Glenda Rodgers; Maryann Gallagher; Shengfu Piao; Andrea B Troxel; Tracey L Evans; Angela M DeMichele; Katherine L Nathanson; Peter J O'Dwyer; Jonathon Kaiser; Laura Pontiggia; Lisa E Davis; Ravi K Amaravadi
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

7.  Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.

Authors:  Reshma Rangwala; Yunyoung C Chang; Janice Hu; Kenneth M Algazy; Tracey L Evans; Leslie A Fecher; Lynn M Schuchter; Drew A Torigian; Jeffrey T Panosian; Andrea B Troxel; Kay-See Tan; Daniel F Heitjan; Angela M DeMichele; David J Vaughn; Maryann Redlinger; Abass Alavi; Jonathon Kaiser; Laura Pontiggia; Lisa E Davis; Peter J O'Dwyer; Ravi K Amaravadi
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

8.  A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.

Authors:  Myrna R Rosenfeld; Xiaobu Ye; Jeffrey G Supko; Serena Desideri; Stuart A Grossman; Steven Brem; Tom Mikkelson; Daniel Wang; Yunyoung C Chang; Janice Hu; Quentin McAfee; Joy Fisher; Andrea B Troxel; Shengfu Piao; Daniel F Heitjan; Kay-See Tan; Laura Pontiggia; Peter J O'Dwyer; Lisa E Davis; Ravi K Amaravadi
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016
  8 in total
  43 in total

1.  The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy.

Authors:  David A Gewirtz
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

Review 2.  Molecular definitions of autophagy and related processes.

Authors:  Lorenzo Galluzzi; Eric H Baehrecke; Andrea Ballabio; Patricia Boya; José Manuel Bravo-San Pedro; Francesco Cecconi; Augustine M Choi; Charleen T Chu; Patrice Codogno; Maria Isabel Colombo; Ana Maria Cuervo; Jayanta Debnath; Vojo Deretic; Ivan Dikic; Eeva-Liisa Eskelinen; Gian Maria Fimia; Simone Fulda; David A Gewirtz; Douglas R Green; Malene Hansen; J Wade Harper; Marja Jäättelä; Terje Johansen; Gabor Juhasz; Alec C Kimmelman; Claudine Kraft; Nicholas T Ktistakis; Sharad Kumar; Beth Levine; Carlos Lopez-Otin; Frank Madeo; Sascha Martens; Jennifer Martinez; Alicia Melendez; Noboru Mizushima; Christian Münz; Leon O Murphy; Josef M Penninger; Mauro Piacentini; Fulvio Reggiori; David C Rubinsztein; Kevin M Ryan; Laura Santambrogio; Luca Scorrano; Anna Katharina Simon; Hans-Uwe Simon; Anne Simonsen; Nektarios Tavernarakis; Sharon A Tooze; Tamotsu Yoshimori; Junying Yuan; Zhenyu Yue; Qing Zhong; Guido Kroemer
Journal:  EMBO J       Date:  2017-06-08       Impact factor: 11.598

Review 3.  Glutaminolysis and autophagy in cancer.

Authors:  Victor H Villar; Faten Merhi; Mojgan Djavaheri-Mergny; Raúl V Durán
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

4.  Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells.

Authors:  Hojin Yeom; Sung-Hee Hwang; Hye-Gyo Kim; Michael Lee
Journal:  Toxicol Res       Date:  2021-10-11

Review 5.  Hydroxychloroquine retinopathy.

Authors:  I H Yusuf; S Sharma; R Luqmani; S M Downes
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

6.  Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target.

Authors:  Jacob New; Levi Arnold; Megha Ananth; Sameer Alvi; Mackenzie Thornton; Lauryn Werner; Ossama Tawfik; Hongying Dai; Yelizaveta Shnayder; Kiran Kakarala; Terance T Tsue; Douglas A Girod; Wen-Xing Ding; Shrikant Anant; Sufi Mary Thomas
Journal:  Cancer Res       Date:  2017-09-28       Impact factor: 12.701

Review 7.  Autophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer.

Authors:  Tareq Saleh; Laurie Cuttino; David A Gewirtz
Journal:  Biochim Biophys Acta       Date:  2016-06-15

8.  JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy.

Authors:  Irina A Vasilevskaya; Muthu Selvakumaran; David Roberts; Peter J O'Dwyer
Journal:  Mol Cancer Res       Date:  2016-05-23       Impact factor: 5.852

9.  Autophagy modulator scoring system: a user-friendly tool for quantitative analysis of methodological integrity of chemical autophagy modulator studies.

Authors:  Yu Dong; Yuanjia Hu; Sovan Sarkar; Wei-Xing Zong; Min Li; Du Feng; Ju-Xian Song; Min Li; Diego L Medina; Jieqiong Tan; Zhuohua Zhang; Zhenyu Yue; Jia-Hong Lu
Journal:  Autophagy       Date:  2019-12-23       Impact factor: 13.391

10.  Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy.

Authors:  Katy J Petherick; Owen J L Conway; Chido Mpamhanga; Simon A Osborne; Ahmad Kamal; Barbara Saxty; Ian G Ganley
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.